about
Molecular genetics of successful smoking cessation: convergent genome-wide association study resultsEffect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trialAnticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?A research agenda for assessing the potential contribution of genomic medicine to tobacco control.Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact of communication upon adherence.Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar DisorderCHRNA3 rs1051730 genotype and short-term smoking cessationEthical concerns related to developing pharmacogenomic treatment strategies for addiction.Gender-stratified gene and gene-treatment interactions in smoking cessationUnwarranted optimism in media portrayals of genetic research on addiction overshadows critical ethical and social concerns.Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trialIs attributing smoking to genetic causes associated with a reduced probability of quit attempt success? A cohort study.Computational modeling and multilevel cancer control interventions.A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessationCurrent and emerging pharmacotherapies for treating tobacco dependence.Overview of the pharmacogenomics of cigarette smoking.Association between dopamine transporter genotypes and smoking cessation: a meta-analysis.Black and White adults' perspectives on the genetics of nicotine addiction susceptibilityPrimary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristicsPharmacogenetics of alcohol, nicotine and drug addiction treatments.Association of the mu-opioid receptor gene with smoking cessation.Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.Prospective association of dopamine-related polymorphisms with smoking cessation in general care.Are smokers interested in genetic testing for smoking addiction? A socio-cognitive approach.Lack of Association of OPRM1 Genotype and Smoking CessationResearch HighlightsEffects of dopamine D2 receptor gene polymorphisms on smoking cessation: abstinence and withdrawal symptomsCan pharmacogenetics help smokers quit?
P2860
Q24653819-12DDEF9B-F862-4EF1-9FB8-0EBB673D7C71Q28730647-48F9685C-5D6C-46E5-BCD5-E780E33139E7Q30229059-F14E5D0A-6ABF-4790-8E1B-C87D8E059813Q30230101-205D5676-E221-42A1-9EC2-B47003D559DFQ31138857-BB2AB83A-B023-46C6-B054-54FE835CB2EFQ33742746-244AB0A7-A36C-4DA3-9873-2CFC72C50927Q35196495-8CB64195-2ADC-4D3A-A2B8-26C7C6525524Q35231050-E35B4E52-7E3F-4B4A-BCAA-1F57BCE5E033Q35286480-9C6B1DFE-99C5-4307-9C77-EE7304036595Q35523896-D191649C-931F-4C09-959A-92FADA62A7EFQ35671471-2F9705F5-85CE-4CBD-AE22-0BA008280D72Q36076504-5A519E15-2FC2-4F60-B395-C2FC7D77CC22Q36088677-52B7B989-0C32-42E3-A790-65A447ACBE34Q36352839-9F401826-E22E-4A79-99A1-C952E2EDA8D9Q36481665-85995E50-9CE9-4052-9526-69D8B354CCC1Q36580581-4C34D68D-9CA0-42D4-9C16-002882CAD504Q36708951-5DC31B33-DBC0-4F38-8628-1632E4B73F6EQ36825062-BE2016A4-96DE-4B14-9CE6-3B69B41C6E4BQ37066274-9722CF3E-DCB1-44D4-BD22-9F3EEB525533Q37270506-CD0141D0-BB7A-4382-A95F-48CAD1229EF7Q37848476-08D5156C-3CF2-497A-BD0B-E227B0002278Q40251616-4CBEA7AD-709C-4386-B1E6-336F6E18AA80Q41676984-1BFB4E7E-63F9-4F92-9FDF-1601A42683E5Q43115874-5946D4B2-E99A-46A5-9834-FF5028CA4759Q45356667-6C0FBA9C-DB0F-47E5-A02D-51F8C1DAA908Q57380378-49684D21-D892-4D68-8183-B99F0A7375E3Q57380785-36245EF6-08B4-45FE-9191-51125798F80DQ57380847-C86E98C4-18B2-40A2-BD97-47C80E454529Q57380880-734F5BB9-018C-4232-A5AC-D434F435B00B
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacogenetics and nicotine addiction treatment.
@ast
Pharmacogenetics and nicotine addiction treatment.
@en
type
label
Pharmacogenetics and nicotine addiction treatment.
@ast
Pharmacogenetics and nicotine addiction treatment.
@en
prefLabel
Pharmacogenetics and nicotine addiction treatment.
@ast
Pharmacogenetics and nicotine addiction treatment.
@en
P2093
P2860
P356
P1433
P1476
Pharmacogenetics and nicotine addiction treatment.
@en
P2093
Alexandra E Shields
Freda Patterson
Wade H Berrettini
P2860
P304
P356
10.1517/14622416.6.3.211
P577
2005-04-01T00:00:00Z